Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Assets Average (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Assets Average for 15 consecutive years, with $156.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average rose 26.75% to $156.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $156.0 million, a 26.75% increase, with the full-year FY2024 number at $121.0 million, up 20.2% from a year prior.
  • Assets Average was $156.0 million for Q3 2025 at Gyre Therapeutics, up from $141.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $156.0 million in Q3 2025 to a low of $11.2 million in Q3 2023.
  • A 5-year average of $87.1 million and a median of $90.2 million in 2021 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: tumbled 80.45% in 2023, then soared 1001.03% in 2024.
  • Gyre Therapeutics' Assets Average stood at $67.1 million in 2021, then fell by 13.73% to $57.9 million in 2022, then increased by 9.27% to $63.3 million in 2023, then skyrocketed by 98.13% to $125.3 million in 2024, then increased by 24.49% to $156.0 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Assets Average are $156.0 million (Q3 2025), $141.2 million (Q2 2025), and $127.6 million (Q1 2025).